Analyst Ratings for [SANA] Sana Biotechnology Inc.

9/24/25	Initiated	Outperform	X
SANA Sana Biotechnology Wedbush
$5
7/3/25	Resumed	Overweight	X
SANA Sana Biotechnology Morgan Stanley
$12
3/18/25	Upgrades	Mkt Perform Mkt Outperform	X
SANA Sana Biotechnology Citizens JMP
$5
1/8/25	Upgrades	Hold Buy	X
SANA Sana Biotechnology TD Cowen
11/5/24	Downgrades	Mkt Outperform Mkt Perform	X
SANA Sana Biotechnology JMP Securities
6/26/24	Initiated	Buy	X
SANA Sana Biotechnology Rodman & Renshaw
$16
1/16/24	Upgrades	Neutral Buy	X
SANA Sana Biotechnology H.C. Wainwright
$12
9/5/23	Initiated	Buy	X
SANA Sana Biotechnology Citigroup
$8
8/14/23	Initiated	Market Perform	X
SANA Sana Biotechnology TD Cowen
5/2/23	Initiated	Neutral	X
SANA Sana Biotechnology H.C. Wainwright
3/1/21	Initiated	Buy	X
SANA Sana Biotechnology BofA Securities
$45
3/1/21	Initiated	Neutral	X
SANA Sana Biotechnology Goldman
$40
3/1/21	Initiated	Neutral	X
SANA Sana Biotechnology JP Morgan
$35
3/1/21	Initiated	Overweight	X
SANA Sana Biotechnology Morgan Stanley
$40

SANA Sana Biotechnology Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.